文献速递免疫规划慢病防控与筛查

他汀使用对流感疫苗接种老年人就医急性呼吸道疾病风险的影响

Effect of statin use on the risk of medically attended acute respiratory illness among influenza vaccinated elderly.
PubMed 文献 · Vaccine · 2018-08-31

本研究基于台湾全民健康保险研究数据库开展回顾性队列研究,纳入2007-2008至2012-2013流感季接种季节性流感疫苗的66岁及以上老年人共440,180名,比较他汀使用者与非使用者就医急性呼吸道疾病(MAARI)风险。总体他汀使用者MAARI风险高于非使用者(OR 1.03,95%CI 1.02-1.05),接种后他汀暴露与MAARI风险升高相关(OR 1.05,95%CI 1.02-1.07);辛伐他汀(OR 1.14,95%CI 1.10-1.18)和洛伐他汀(OR 1.18,95%CI 1.12-1.25)与MAARI风险显著增加相关。

要点

  • 接种流感疫苗的老年人中,他汀使用者MAARI风险高于非使用者(OR 1.03,95%CI 1.02-1.05)。
  • 接种后他汀暴露与MAARI风险升高相关(OR 1.05,95%CI 1.02-1.07)。
  • 辛伐他汀和洛伐他汀与MAARI风险显著增加相关(OR分别为1.14和1.18)。

核心结论

  • 他汀暴露,尤其是辛伐他汀和洛伐他汀,与季节性流感疫苗接种老年人MAARI风险升高相关。

研究设计与样本

  • 回顾性队列研究,使用台湾全民健康保险研究数据库,纳入2007-2008至2012-2013流感季接种季节性流感疫苗的66岁及以上老年人共440,180名,采用倾向评分匹配和条件逻辑回归模型分析。

主要发现

  • 总体他汀使用者MAARI风险高于非使用者(OR 1.03,95%CI 1.02-1.05)。
  • 接种后他汀暴露与MAARI风险升高相关(OR 1.05,95%CI 1.02-1.07)。
  • 辛伐他汀使用与MAARI风险显著增加相关(OR 1.14,95%CI 1.10-1.18)。
  • 洛伐他汀使用与MAARI风险显著增加相关(OR 1.18,95%CI 1.12-1.25)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The immunomodulatory effects of statins may reduce the immune response induced by influenza vaccines. However, evidence regarding the effect of statin use on the effectiveness of seasonal influenza vaccines against medically attended acute respiratory illness (MAARI) in the elderly remains scarce. METHODS: We conducted a retrospective cohort study using data from Taiwan's National Health Insurance Research Database. Elderly adults aged ≧ 66 years who were vaccinated with seasonal influenza vaccines during the 2007-2008 to 2012-2013 influenza seasons were enrolled for this analysis. We compared the risk of MAARI between statin and non-statin users. Propensity score matching and conditional logistic regression models were used to analyze the data. RESULTS: A total of 440,180 elderly were included in this study. In general, the risk of MAARI was higher in statin users than non-statin users (odds ratio [OR]: 1.03, 95% confidence interval [CI]: 1.02-1.05). Statin exposure after vaccination was associated with a higher risk of MAARI (OR: 1.05, 95% CI: 1.02-1.07). Among different statin agents, simvastatin and lovastatin use was associated with a significant increase in the risk of MAARI (ORsimvastatin: 1.14, 95% CI: 1.10-1.18; ORlovastatin: 1.18, 95% CI: 1.12-1.25). CONCLUSIONS: Statin exposure, especially simvastatin and lovastatin, was associated with a higher risk of MAARI in the seasonal influenza vaccinated elderly. Future studies exploring the differences between individual statins and mechanisms of their immunomodulatory effects are necessary.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chiu HT, Shen LJ, Chen YC, et al. Effect of statin use on the risk of medically attended acute respiratory illness among influenza vaccinated elderly. Vaccine. 2018. PMID: 30174239. doi:10.1016/j.vaccine.2018.08.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。